Finding the right balance between efficacy and tolerability for TB treatment: the search continues Institute of Tropical Medicine
Low cycle threshold value in Xpert MTB/RIF assay may herald false detection of tuberculosis and rifampicin resistance: a study of two cases Institute of Tropical Medicine
We report 2 cases for whom Xpert MTB/RIF falsely signaled rifampicin-resistant tuberculosis, based on unusually low cycle threshold and 3 of 5 probes missing. Other mycobacterial tests were negative. Further optimization of the Xpert MTB/RIF algorithm is warranted.
Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown Institute of Tropical Medicine
Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests Institute of Tropical Medicine
Xpert MTB/RIF rapidly detects resistance to rifampicin (RR); however, this test misses I491F-RR conferring rpoB mutation, common in southern Africa. In addition, Xpert MTB/RIF does not distinguish between viable and dead Mycobacterium tuberculosis (MTB). We aimed to investigate the ability of thin-layer agar (TLA) direct drug-susceptibility testing (DST) to detect MTB and its drug-resistance profiles in field conditions in Eswatini. ...
Should treatment of low-level rifampicin mono-resistant tuberculosis be different? Institute of Tropical Medicine
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? Institute of Tropical Medicine
In its 2020 guidelines for the treatment of rifampicin-resistant TB (RR-TB), the WHO recommends all-oral fluoroquinoLone-based regimens, with bedaquiline replacing the second-line injectable drugs (SLIDs). SLIDs were used for their strong acquired resistance-preventing activity. Data from three cohorts showed acquired bedaquiline resistance ranging between 2.5% and 30.8%, with no protection from a SLID in most cases. If bedaquiline resistance ...
Human rights: finding the right balance for rifampicin-resistant TB treatment Institute of Tropical Medicine
HERA: a new era for health emergency preparedness in Europe? Institute of Tropical Medicine
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward Institute of Tropical Medicine
The 2018 World Health Organization (WHO) treatment guidelines for multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB) give preference to all-oral long regimens lasting for 18-20 months. The guidelines strongly recommend combining bedaquiline, levofloxacin (or moxifloxacin) and linezolid, supplemented by cycloserine and/or clofazimine. The effectiveness of this combination in a long regimen has not been tested in any study to date, with ...